Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127646532 | 12764653 | 2 | F | 20160831 | 20160916 | 20160920 | 20160923 | EXP | US-ASTRAZENECA-2016SE99814 | ASTRAZENECA | 18456.00 | DY | F | Y | 77.10000 | KG | 20160924 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127646532 | 12764653 | 1 | PS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 22200 | 2 | MG | /wk | ||||||||
| 127646532 | 12764653 | 2 | SS | BYETTA | EXENATIDE | 1 | Unknown | U | 0 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | |||||||||
| 127646532 | 12764653 | 3 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | U | U | 0 | 40 | MG | QD | ||||||
| 127646532 | 12764653 | 4 | C | INVOKANA | CANAGLIFLOZIN | 1 | Oral | 0 | 300 | MG | QD | ||||||||
| 127646532 | 12764653 | 5 | C | ASPRIDRA | 2 | Subcutaneous | 30 UNITS WITH EACH MEAL WHICH SHE HAS BEEN ON FOR 2 YEARS | 0 | INJECTION | ||||||||||
| 127646532 | 12764653 | 6 | C | TOUJEO | INSULIN GLARGINE | 1 | Subcutaneous | 80 UNITS DAILY STARTED 6 MONTHS AGO | 0 | INJECTION | |||||||||
| 127646532 | 12764653 | 7 | C | ZOLPIDEM | ZOLPIDEMOLPIDEM TARTRATE | 1 | Oral | 6.25MG AS REQUIRED | 0 | 6.25 | MG | ||||||||
| 127646532 | 12764653 | 8 | C | LOSARTAN. | LOSARTAN | 1 | 0 | 25 | MG | QD | |||||||||
| 127646532 | 12764653 | 9 | C | DULOXETINE. | DULOXETINE | 1 | Oral | 0 | 60 | MG | QD | ||||||||
| 127646532 | 12764653 | 10 | C | NEURONTIN | GABAPENTIN | 1 | 0 | 300 | MG | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127646532 | 12764653 | 1 | Type 2 diabetes mellitus |
| 127646532 | 12764653 | 3 | Gastrooesophageal reflux disease |
| 127646532 | 12764653 | 4 | Type 2 diabetes mellitus |
| 127646532 | 12764653 | 5 | Type 2 diabetes mellitus |
| 127646532 | 12764653 | 6 | Type 2 diabetes mellitus |
| 127646532 | 12764653 | 7 | Sleep disorder |
| 127646532 | 12764653 | 8 | Renal disorder |
| 127646532 | 12764653 | 9 | Depression |
| 127646532 | 12764653 | 10 | Pain |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127646532 | 12764653 | OT |
| 127646532 | 12764653 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127646532 | 12764653 | Anaphylactic shock | |
| 127646532 | 12764653 | Apparent death | |
| 127646532 | 12764653 | Back pain | |
| 127646532 | 12764653 | Gastrooesophageal reflux disease |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |